

## SUPPLEMENTARY TABLES

**Table S1**

EC<sub>50</sub> values for ANXA2 KD and control cells treated with H<sub>2</sub>O<sub>2</sub> and chemotherapeutic agents.

<b>Cell line</b>	<b>H<sub>2</sub>O<sub>2</sub> treatment (EC<sub>50</sub>)</b>	<b>Standard deviation (StDev)</b>
MCF7 p36 shRNA2	1.07 mM	± 0.056 mM
MCF7 p36 scramble	4.377 mM	± 0.707 mM
TIME p36 shRNA2	0.462 mM	± 0.007 mM
TIME p36 scramble	0.682 mM	± 0.008 mM
LLC p36 shRNA3	0.797 mM	± 0.178 mM
LLC p36 scramble	6.605 mM	± 0.876 mM
<b>Cell line</b>	<b>Etoposide treatment (EC<sub>50</sub>)</b>	<b>Standard deviation (StDev)</b>
MCF7 p36 shRNA2	0.189 µM	± 0.019 µM
MCF7 p36 scramble	0.645 µM	± 0.296 µM
TIME p36 shRNA2	0.0163 µM	± 0.005 µM
TIME p36 scramble	0.133 µM	± 0.053 µM
LLC p36 shRNA3	0.01 µM	± 0.0015 µM
LLC p36 scramble	0.25 µM	± 0.12 µM
<b>Cell line</b>	<b>Tamoxifen treatment (EC<sub>50</sub>)</b>	<b>Standard deviation (StDev)</b>
MCF7 p36 shRNA2	12.5 µM	± 3 µM
MCF7 p36 scramble	17.1 µM	± 1 µM
<b>Cell line</b>	<b>Doxorubicin treatment (EC<sub>50</sub>)</b>	<b>Standard deviation (StDev)</b>
TIME p36 shRNA2	4.85 µM	± 0.5 µM
TIME p36 scramble	31.2 µM	± 10.6 µM
LLC p36 shRNA3	3.1 µM	± 0.53 µM
LLC p36 scramble	36.2 µM	± 2.6 µM